Updated from 11:47 a.m. EST Shares of Mylan (MYL) were on the rise Tuesday morning after the drugmaker said it had started selling a generic version of Bristol-Myers Squibb's (BMY) HIV drug Zerit.
Matrix Laboratories, an Indian company owned in large part by Mylan, received final approval Monday from the Food and Drug Administration for stavudine capsules in 15, 20, 30 and 40 mg doses, Mylan said. The product was shipped immediately under the Mylan Pharmaceutical Inc. label, Mylan said. Mylan shares ended Tuesday's trading session up 17 cents, or 1.8%, to $9.68. Bristol-Myer's Zerit had annual U.S. sales of approximately $54 million for the 12 months ending Sept. 30 for the strengths noted above, Mylan said. Mylan's competitors in the generic-drug sector include Teva Pharmaceuticals (TEVA) and Watson Pharmaceuticals (WPI). Other companies that make generic drugs used to treat HIV include Barr Laboratories, Aurobindo Pharma, Cipla, Ranbaxy Laboratories and Roxane Laboratories.>To order reprints of this article, click here: ReprintsTheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,801.23 | 1,342.64 | 2,903.88 | 19.69 |
Oil *
117.67
|
|
DOWN
89.23 |
DOWN
9.31 |
DOWN
23.35 |
DOWN
0.78 |
10 Yr
1.97%
SPDR Gold
167.14
|
|
-0.69%
|
-0.69%
|
-0.80%
|
-3.81%
|
Data delayed 20 minutes |
Connect with TheStreet